Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

153.40 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EDT, Apr 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	27
Open	153.40
Bid (Size)	150.50 (100)
Ask (Size)	160.50 (200)
Prev. Close	153.40
Today's Range	153.40 - 153.40
52wk Range	63.81 - 212.75
Shares Outstanding	115,246,666
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Performance

YTD	-13.4%	-13.4%
1 Month	+6.1%	+6.1%
3 Month	-6.3%	-6.3%
6 Month	-4.9%	-4.9%
1 Year	+116.0%	+116.0%

More News

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

Via The Motley Fool

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

Via The Motley Fool

The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026

March 09, 2026

Via MarketMinute

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

Via The Motley Fool

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Via The Motley Fool

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

Via The Motley Fool

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

Via The Motley Fool

Insmed (INSM) Q4 2025 Earnings Call Transcript ↗

February 19, 2026

Via The Motley Fool

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Via The Motley Fool

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Via The Motley Fool

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗

January 06, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm

December 29, 2025

From The Schall Law Firm

Via Business Wire

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Via The Motley Fool

Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗

December 17, 2025

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

December 17, 2025

Via Chartmill

Frequently Asked Questions

Is Insmed Incorporated - Common Stock publicly traded?

Yes, Insmed Incorporated - Common Stock is publicly traded.

What exchange does Insmed Incorporated - Common Stock trade on?

Insmed Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Insmed Incorporated - Common Stock?

The ticker symbol for Insmed Incorporated - Common Stock is INSM on the Nasdaq Stock Market

What is the current price of Insmed Incorporated - Common Stock?

The current price of Insmed Incorporated - Common Stock is 153.40

When was Insmed Incorporated - Common Stock last traded?

The last trade of Insmed Incorporated - Common Stock was at 04/14/26 04:15 PM ET

What is the market capitalization of Insmed Incorporated - Common Stock?

The market capitalization of Insmed Incorporated - Common Stock is 17.68B

How many shares of Insmed Incorporated - Common Stock are outstanding?

Insmed Incorporated - Common Stock has 18B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.